ArticleChemical science2017
Protecting microRNAs from RNase degradation with steric DNA nanostructures.
Article in Chemical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Design strategies for programmable oligonucleotide nanotherapeutics.Drug discovery today · 2020Pooled it
- Engineered exosomal miR140 modulates mitophagy of chondrocytes through targeting CAPN1 to alleviate osteoarthritis.Science China. Life sciences · 2025Article
- Keratinocyte-derived circulating microRNAs in extracellular vesicles: a novel biomarker of psoriasis severity and potential therapeutic target.Journal of translational medicine · 2024Article
- MicroRNAs as Mediators of Adipose Thermogenesis and Potential Therapeutic Targets for Obesity.Biology · 2022Review
- Construction of nanocarriers based on nucleic acids and their applications in nanobiology delivery systems.National science review · 2022Article
- Pharmaceutical applications of framework nucleic acids.Acta pharmaceutica Sinica. B · 2022Review
- Exosomally Targeting microRNA23a Ameliorates Microvascular Endothelial Barrier Dysfunction Following Rickettsial Infection.Frontiers in immunology · 2022Article
- Optimized Protocol for Plasma-Derived Extracellular Vesicles Loading with Synthetic miRNA Mimic Using Electroporation.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Functionalizing DNA nanostructures with natural cationic amino acids.Bioactive materials · 2021Article
- Co-delivery of miRNA-15a and miRNA-16-1 using cationic PEGylated niosomes downregulates Bcl-2 and induces apoptosis in prostate cancer cells.Biotechnology letters · 2021Article
- miRNA-mediated alteration of sulfatase modifying factor 1 expression using self-assembled branched DNA nanostructures.RSC advances · 2021Article
- Recent Advances in miRNA Delivery Systems.Methods and protocols · 2021Article
- Recent progress on the role of miR-140 in cartilage matrix remodelling and its implications for osteoarthritis treatment.Arthritis research & therapy · 2020Review
- Nucleic acid-based drug delivery strategies.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Nanoscale Self-Assembly for Therapeutic Delivery.Frontiers in bioengineering and biotechnology · 2020Review
- In Silico and In Cell Analysis of Openable DNA Nanocages for miRNA Silencing.International journal of molecular sciences · 2019Article
- Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs.Molecular therapy. Methods & clinical development · 2019Article
- Substrate specificity-enabled terminal protection for direct quantification of circulating MicroRNA in patient serums.Chemical science · 2019Article
- Static DNA Nanostructures For Cancer Theranostics: Recent Progress In Design And Applications.Nanotechnology, science and applications · 2019Article
- Titanium Dioxide Nanoparticles Enhance Leakiness and Drug Permeability in Primary Human Hepatic Sinusoidal Endothelial Cells.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor suppressive microRNAs are potent molecules that might cure cancer, one day. Despite the many advanced strategies for delivery of these microRNAs to the cell, there are few therapeutic microRNAs in clinical use. Progress in microRNA bioapplications is hindered by a high vulnerability of exogeneous microRNA molecules to RNase degradation that occurs in extra- and intracellular physiological conditions. In this proof-of-concept study, we use a programmable self-assembled DNA nanostructure bearing a "shuriken" shape to not only deliver but more importantly protect a tumor suppressive microRNA-145 for a sufficiently long time to exert its therapeutic effect in human colorectal cancer cells. Our DNA nanostructure harbored complementary sequences that can hybridize with the microRNA cargo. This brings the microRNA-DNA duplex very close to the core structure such that the microRNA cargo becomes sterically shielded from RNase's degradative activity. Our novel DNA nanostructure based protector concept removes the degradative bottleneck that may plague other nucleic acid delivery strategies and presents a new paradigm towards exploiting these microRNAs for anti-cancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.